April 30, 2018 / 8:29 PM / 20 days ago

BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma

April 30 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

* KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE

* KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018

* KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDY’S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE

* KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019

* KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below